Impact of China’s Drug Regulatory Reforms on the Development of Anti-Tumor Drugs
Cancer Communications · 01.01.2026 · 46
DOI: 10.34133/cancomm.0032 ↗Kurz gefasst
Editorial in der Zeitschrift Cancer Communications, online erschienen am 04.06.2026. Verfasst von Ling Tang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation, National Medical Products Administration, Beijing, P. R. China. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Center for Drug Evaluation, National Medical Products Administration, Beijing, P. R. China.
- National Medical Products Administration, Beijing, P. R. China.
ORCID-Profile: Zhimin Yang
Zitieren
APA
Tang, L., Yuan, L., Geng, Y., Yang, Z., & Huang, G. (2026). Impact of China’s Drug Regulatory Reforms on the Development of Anti-Tumor Drugs. Cancer Communications, 46. https://doi.org/10.34133/cancomm.0032
Vancouver
Tang L, Yuan L, Geng Y, Yang Z, Huang G. Impact of China’s Drug Regulatory Reforms on the Development of Anti-Tumor Drugs. Cancer Communications. 2026;46. doi:10.34133/cancomm.0032
BibTeX
@article{Tang2026,
author = {Tang, Ling and Yuan, Lijia and Geng, Ying and Yang, Zhimin and Huang, Guo},
title = {Impact of China’s Drug Regulatory Reforms on the Development of Anti-Tumor Drugs},
journal = {Cancer Communications},
year = {2026},
volume = {46},
doi = {10.34133/cancomm.0032}
}
EUVIMED